Document Detail

Re-inventing intratumoral immunotherapy for melanoma.
MedLine Citation:
PMID:  21554094     Owner:  NLM     Status:  In-Data-Review    
Immunotherapeutics have been applied intratumorally to manage accessible lesions and to induce systemic immunity in malignant melanoma. Intratumoral bacillus Calmette-Guérin (BCG) has been used for 40 years, and intratumoral BCG, IL-2, IFN-α and imiquimod are recommended as treatment options for patients with in-transit melanoma metastases. Regression of cutaneous metastases can be achieved. Subcutaneous metastases are more refractory, and regression of uninjected, visceral metastases is infrequent. Other microbial products, cytokines, chemicals, immune cells, antibody and viral and plasmid vectors expressing immunologically active molecules have been tested. Antitumor activity has not been demonstrated to be superior to that of intratumoral BCG. There are few controlled trials, and whether survival is impacted with any approach has not yet been established. The immunotherapeutics applied and the intratumoral administration procedure itself can activate responses that are immune inhibitory. More rigorous clinical testing and improved understanding and modulation of regulatory immune responses are necessary.
Pierre L Triozzi; Ralph J Tuthill; Ernest Borden
Related Documents :
8142924 - Cytokines and oncogenes in cellular interactions of rheumatoid arthritis.
21157434 - Retroviral vectors induce epigenetic chromatin modifications and il-10 production in tr...
21441454 - Mhc class ii engagement by its ligand lag-3 (cd223) contributes to melanoma resistance ...
18668354 - All-trans-retinoic acid induces apoptosis in leydig cells via activation of the mitocho...
24117794 - Myricetin suppresses lipoteichoic acid-induced interleukin-1β and cyclooxygenase-2 exp...
24179504 - Clinical significance of the induction of macrophage differentiation by the costimulato...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Immunotherapy     Volume:  3     ISSN:  1750-7448     ISO Abbreviation:  Immunotherapy     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-05-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101485158     Medline TA:  Immunotherapy     Country:  England    
Other Details:
Languages:  eng     Pagination:  653-71     Citation Subset:  IM    
Melanoma Program, The Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.
Next Document:  Immunomodulatory cytokines as therapeutic agents for melanoma.